<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00812487</url>
  </required_header>
  <id_info>
    <org_study_id>2008H0087</org_study_id>
    <secondary_id>1R21DK081877-01</secondary_id>
    <nct_id>NCT00812487</nct_id>
  </id_info>
  <brief_title>Glycemic Control and Variability for Congestive Heart Failure Exacerbation</brief_title>
  <official_title>Glycemic Control and Variability for Congestive Heart Failure Exacerbation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kathleen Dungan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High glucose as well as fluctuations (rapid swings) in blood glucose can contribute to severe
      hospital complications and even death.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High glucose as well as fluctuations in blood glucose can contribute to severe hospital
      complications and even death. Studies also suggest that heart failure patients who have high
      glucose or diabetes do not live as long as patients with normal glucose. Glucose fluctuations
      have not been well-studied in patients with heart failure. In this study, we will determine
      whether better control of blood sugar fluctuations in the hospital improve outcomes. We will
      enroll 80 patients with severe heart failure and divide them into 2 groups. We will use
      intravenous (given through the vein) insulin to lower blood sugar levels in group 1, and
      insulin injections (under the skin) in group 2. We will determine whether intravenous insulin
      improves blood markers of inflammation, changes in vital signs, and other tests that predict
      mortality in patients with heart failure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>participants were followed for the duration of hospital stay, median hospital stay 8 day</time_frame>
    <description>Duration of hospitalization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospital Readmission</measure>
    <time_frame>30 days</time_frame>
    <description>All-cause hospital readmission within 30 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>High Frequency Heart Rate Variability</measure>
    <time_frame>24 hours</time_frame>
    <description>High frequency heart rate variability (HF HRV)is a measure of cardiac autonomic tone. Electrocardiographic measures were obtained using a Bionex system (Mindware, Gahanna, OH). The electrocardiogram was performed in the standard lead II configuration. Software (Mindware, Gahanna, OH) was used to derive HF HRV. HF HRV was calculated using power spectral analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-ejection Period (PEP)</measure>
    <time_frame>24 hours</time_frame>
    <description>Pre-ejection period (PEP) is the time between the onset of electrical depolarization of the ventricle and the opening of the aortic valve, a measure of sympathetic tone. It is obtained noninvasively using cardiac impedance obtained using a Bionex system (Mindware, Gahanna, OH). PEP is measured in milliseconds; lower values reflect higher sympathetic tone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Sensitivity C-reactive Protein (Hs-CRP)</measure>
    <time_frame>72 hours</time_frame>
    <description>High sensitivity C-reactive Protein (hs-CRP) is a measure of inflammation. hsCRP (range 0-15 mg/L) was performed using Immunlite 1000 assay (Siemens; Erlangen, Germany).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain Natriuretic Peptide (BNP)</measure>
    <time_frame>72 hours</time_frame>
    <description>Laboratory analyses were performed by the study institution's Clinical Research Center using standard commercial kits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>30 days</time_frame>
    <description>Quality of Life was measured using the Minnesota Living with Heart Failure Questionnaire, which is a 21 question survey that uses a likert scale of 0-5. Each item asks over the past 4 weeks whether they have had a particular symptom of heart failure and to classify the response as no symptoms (0) to having the symptom very much (5). Responses are summed for a total score (0-105).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic Lability Index (GLI)</measure>
    <time_frame>24 hours</time_frame>
    <description>GLI is a measure of glycemic variability. GLI is the sum of the square of the difference between successive glucose measurements divided by the difference in time between measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coefficient of Variation (CV)</measure>
    <time_frame>24 hours</time_frame>
    <description>CV is a measure of glycemic variability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Glucose</measure>
    <time_frame>24 hours</time_frame>
    <description>mean sensor glucose</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Congestive Heart Failure</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Intravenous insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcutaneous Insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 injections of insulin/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous insulin</intervention_name>
    <description>Patients will receive continuous insulin infusion through the vein.</description>
    <arm_group_label>Intravenous insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subcutaneous insulin</intervention_name>
    <description>4 injections of insulin/day</description>
    <arm_group_label>Subcutaneous Insulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 and above

          -  Admitted (less than 48 hours) to the with worsening heart failure

          -  Hyperglycemia or diabetes. Hyperglycemia is defined as blood glucose greater than 150
             mg/dL on at least 2 occasions separated by at least 4 hours apart, insulin use, or
             HbA1c &gt;6.5%.

        Exclusion Criteria:

          -  Type 1 diabetes

          -  Receiving comfort care measures only

          -  Hospital stay expected to be less than 2 days

          -  Pregnancy

          -  Prisoners

          -  Participation in the study on prior hospitalizations

          -  Acute myocardial infarction within 3 months

          -  End stage renal or liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen M Dungan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2008</study_first_submitted>
  <study_first_submitted_qc>December 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2008</study_first_posted>
  <results_first_submitted>September 6, 2013</results_first_submitted>
  <results_first_submitted_qc>November 9, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 31, 2013</results_first_posted>
  <last_update_submitted>November 9, 2013</last_update_submitted>
  <last_update_submitted_qc>November 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Kathleen Dungan</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>congestive heart failure</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>hyperglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Hospitalized patients with type 2 diabetes and heart failure exacerbation were recruited between 2008-2013 from an academic medical center.</recruitment_details>
      <pre_assignment_details>Patients were randomized to intravenous or subcutaneous insulin. There were no pre-assignment changes in therapy before randomization. One patient was excluded after consent but prior to randomization due to receipt of corticosteroids which is an exclusion criterion.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intravenous Insulin</title>
          <description>Patients received intravenous insulin according to the hospital nursing run algorithm with a target glucose of 100-150 mg/dl.</description>
        </group>
        <group group_id="P2">
          <title>Subcutaneous Insulin</title>
          <description>Patients received basal and bolus insulin, approximately 5 injections of insulin/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transfer to ICU prior to intervention</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients were excluded from the analyses as described in &quot;Participant Flow&quot;</population>
      <group_list>
        <group group_id="B1">
          <title>Intravenous Insulin</title>
          <description>Patients received intravenous insulin according to the hospital nursing run algorithm with a target glucose of 100-150 mg/dl.</description>
        </group>
        <group group_id="B2">
          <title>Subcutaneous Insulin</title>
          <description>Patients received basal and bolus insulin, approximately 5 injections of insulin/day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="9.6"/>
                    <measurement group_id="B2" value="61.3" spread="12.4"/>
                    <measurement group_id="B3" value="61" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>High Frequency Heart Rate Variability</title>
        <description>High frequency heart rate variability (HF HRV)is a measure of cardiac autonomic tone. Electrocardiographic measures were obtained using a Bionex system (Mindware, Gahanna, OH). The electrocardiogram was performed in the standard lead II configuration. Software (Mindware, Gahanna, OH) was used to derive HF HRV. HF HRV was calculated using power spectral analysis.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Insulin</title>
            <description>Patients received intravenous insulin according to the hospital nursing run algorithm with a target glucose of 100-150 mg/dl.</description>
          </group>
          <group group_id="O2">
            <title>Subcutaneous Insulin</title>
            <description>Patients received basal and bolus insulin, approximately 5 injections of insulin/day</description>
          </group>
        </group_list>
        <measure>
          <title>High Frequency Heart Rate Variability</title>
          <description>High frequency heart rate variability (HF HRV)is a measure of cardiac autonomic tone. Electrocardiographic measures were obtained using a Bionex system (Mindware, Gahanna, OH). The electrocardiogram was performed in the standard lead II configuration. Software (Mindware, Gahanna, OH) was used to derive HF HRV. HF HRV was calculated using power spectral analysis.</description>
          <units>ms^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" lower_limit="1.4" upper_limit="58"/>
                    <measurement group_id="O2" value="13.9" lower_limit="2.7" upper_limit="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-ejection Period (PEP)</title>
        <description>Pre-ejection period (PEP) is the time between the onset of electrical depolarization of the ventricle and the opening of the aortic valve, a measure of sympathetic tone. It is obtained noninvasively using cardiac impedance obtained using a Bionex system (Mindware, Gahanna, OH). PEP is measured in milliseconds; lower values reflect higher sympathetic tone.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Insulin</title>
            <description>Patients received intravenous insulin according to the hospital nursing run algorithm with a target glucose of 100-150 mg/dl.</description>
          </group>
          <group group_id="O2">
            <title>Subcutaneous Insulin</title>
            <description>Patients received basal and bolus insulin, approximately 5 injections of insulin/day</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-ejection Period (PEP)</title>
          <description>Pre-ejection period (PEP) is the time between the onset of electrical depolarization of the ventricle and the opening of the aortic valve, a measure of sympathetic tone. It is obtained noninvasively using cardiac impedance obtained using a Bionex system (Mindware, Gahanna, OH). PEP is measured in milliseconds; lower values reflect higher sympathetic tone.</description>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" spread="24"/>
                    <measurement group_id="O2" value="117" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High Sensitivity C-reactive Protein (Hs-CRP)</title>
        <description>High sensitivity C-reactive Protein (hs-CRP) is a measure of inflammation. hsCRP (range 0-15 mg/L) was performed using Immunlite 1000 assay (Siemens; Erlangen, Germany).</description>
        <time_frame>72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Insulin</title>
            <description>Patients received intravenous insulin according to the hospital nursing run algorithm with a target glucose of 100-150 mg/dl.</description>
          </group>
          <group group_id="O2">
            <title>Subcutaneous Insulin</title>
            <description>Patients received basal and bolus insulin, approximately 5 injections of insulin/day</description>
          </group>
        </group_list>
        <measure>
          <title>High Sensitivity C-reactive Protein (Hs-CRP)</title>
          <description>High sensitivity C-reactive Protein (hs-CRP) is a measure of inflammation. hsCRP (range 0-15 mg/L) was performed using Immunlite 1000 assay (Siemens; Erlangen, Germany).</description>
          <units>mg/dl</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="5.2" upper_limit="26"/>
                    <measurement group_id="O2" value="15.9" lower_limit="8.3" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brain Natriuretic Peptide (BNP)</title>
        <description>Laboratory analyses were performed by the study institution's Clinical Research Center using standard commercial kits</description>
        <time_frame>72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Insulin</title>
            <description>Patients received intravenous insulin according to the hospital nursing run algorithm with a target glucose of 100-150 mg/dl.</description>
          </group>
          <group group_id="O2">
            <title>Subcutaneous Insulin</title>
            <description>Patients received basal and bolus insulin, approximately 5 injections of insulin/day</description>
          </group>
        </group_list>
        <measure>
          <title>Brain Natriuretic Peptide (BNP)</title>
          <description>Laboratory analyses were performed by the study institution's Clinical Research Center using standard commercial kits</description>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="360" lower_limit="167" upper_limit="878"/>
                    <measurement group_id="O2" value="299" lower_limit="135" upper_limit="713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life</title>
        <description>Quality of Life was measured using the Minnesota Living with Heart Failure Questionnaire, which is a 21 question survey that uses a likert scale of 0-5. Each item asks over the past 4 weeks whether they have had a particular symptom of heart failure and to classify the response as no symptoms (0) to having the symptom very much (5). Responses are summed for a total score (0-105).</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Insulin</title>
            <description>Patients received intravenous insulin according to the hospital nursing run algorithm with a target glucose of 100-150 mg/dl.</description>
          </group>
          <group group_id="O2">
            <title>Subcutaneous Insulin</title>
            <description>Patients received basal and bolus insulin, approximately 5 injections of insulin/day</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life</title>
          <description>Quality of Life was measured using the Minnesota Living with Heart Failure Questionnaire, which is a 21 question survey that uses a likert scale of 0-5. Each item asks over the past 4 weeks whether they have had a particular symptom of heart failure and to classify the response as no symptoms (0) to having the symptom very much (5). Responses are summed for a total score (0-105).</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5" lower_limit="25" upper_limit="74.5"/>
                    <measurement group_id="O2" value="45" lower_limit="22.5" upper_limit="71.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycemic Lability Index (GLI)</title>
        <description>GLI is a measure of glycemic variability. GLI is the sum of the square of the difference between successive glucose measurements divided by the difference in time between measurements</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Insulin</title>
            <description>Patients received intravenous insulin according to the hospital nursing run algorithm with a target glucose of 100-150 mg/dl.</description>
          </group>
          <group group_id="O2">
            <title>Subcutaneous Insulin</title>
            <description>Patients received basal and bolus insulin, approximately 5 injections of insulin/day</description>
          </group>
        </group_list>
        <measure>
          <title>Glycemic Lability Index (GLI)</title>
          <description>GLI is a measure of glycemic variability. GLI is the sum of the square of the difference between successive glucose measurements divided by the difference in time between measurements</description>
          <units>(mg/dl)^2/hr*day-1</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" lower_limit="0.31" upper_limit="1.44"/>
                    <measurement group_id="O2" value="0.66" lower_limit="0.29" upper_limit="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hospital Length of Stay</title>
        <description>Duration of hospitalization</description>
        <time_frame>participants were followed for the duration of hospital stay, median hospital stay 8 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Insulin</title>
            <description>Patients received intravenous insulin according to the hospital nursing run algorithm with a target glucose of 100-150 mg/dl.</description>
          </group>
          <group group_id="O2">
            <title>Subcutaneous Insulin</title>
            <description>Patients received basal and bolus insulin, approximately 5 injections of insulin/day</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Length of Stay</title>
          <description>Duration of hospitalization</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="5" upper_limit="10.5"/>
                    <measurement group_id="O2" value="8" lower_limit="5" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hospital Readmission</title>
        <description>All-cause hospital readmission within 30 days</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Insulin</title>
            <description>Patients received intravenous insulin according to the hospital nursing run algorithm with a target glucose of 100-150 mg/dl.</description>
          </group>
          <group group_id="O2">
            <title>Subcutaneous Insulin</title>
            <description>Patients received basal and bolus insulin, approximately 5 injections of insulin/day</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Readmission</title>
          <description>All-cause hospital readmission within 30 days</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Coefficient of Variation (CV)</title>
        <description>CV is a measure of glycemic variability</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Insulin</title>
            <description>Patients received intravenous insulin according to the hospital nursing run algorithm with a target glucose of 100-150 mg/dl.</description>
          </group>
          <group group_id="O2">
            <title>Subcutaneous Insulin</title>
            <description>Patients received basal and bolus insulin, approximately 5 injections of insulin/day</description>
          </group>
        </group_list>
        <measure>
          <title>Coefficient of Variation (CV)</title>
          <description>CV is a measure of glycemic variability</description>
          <units>percentage (mean glucose/SD)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" spread="10.2"/>
                    <measurement group_id="O2" value="18.6" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Glucose</title>
        <description>mean sensor glucose</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Insulin</title>
            <description>Patients received intravenous insulin according to the hospital nursing run algorithm with a target glucose of 100-150 mg/dl.</description>
          </group>
          <group group_id="O2">
            <title>Subcutaneous Insulin</title>
            <description>Patients received basal and bolus insulin, approximately 5 injections of insulin/day</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Glucose</title>
          <description>mean sensor glucose</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139" spread="23"/>
                    <measurement group_id="O2" value="169" spread="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intravenous Insulin</title>
          <description>Patients received intravenous insulin according to the hospital nursing run algorithm with a target glucose of 100-150 mg/dl.</description>
        </group>
        <group group_id="E2">
          <title>Subcutaneous Insulin</title>
          <description>Patients received basal and bolus insulin, approximately 5 injections of insulin/day</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>30 day death</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Any new arrhythmia (such as Ventricular tachycardia, atrial fibrillation) post-randomization</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>Any new infection post-intervention</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Renal Failure</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>New hemodialysis or creatinine &gt;2 mg/dl post-randomization</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mechanical ventilation</sub_title>
                <description>Any mechanical ventilation during hospital stay</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <description>Hypoglycemia, defined as any capillary blood glucose &lt;70 mg/dl during the intervention period (72 hours)</description>
                <counts group_id="E1" events="25" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E2" events="11" subjects_affected="4" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was limited by study drop-out. Sensor glucose values were reduced due to sensor failures, and cardiac assessments were limited due to a high number of patients with ectopy, arrhythmia or paced rhythms at baseline precluding analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kathleen Dungan, MD, MPH</name_or_title>
      <organization>Ohio State University</organization>
      <phone>614-685-3333</phone>
      <email>kathleen.dungan@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

